The researchers found no significant effect on any other type of cancer.


The chemopreventive effect was strongest in years 10-19, when the hazard ratio for aspirin users was 0.60, but a significantly reduced hazard ratio of 0.74 was seen in years 20 and later for the subjects who took aspirin. No significant chemopreventive effect was seen at 0-9 years (hazard ration 0.92).

The British Doctors Aspirin Trial randomized doctors in 1978 and 1979 into a group of 3,429 taking a daily dose of 500 mg of aspirin and a control group of 1,710 who took nothing. Treatment continued for 5-6 years.

The UK Transient Ischaemic Attack Aspirin Trial randomized 2,449 patients over age 40 who had already experienced a transient ischemic attack or mild ischemic stroke to receive daily doses of either 1,200 mg of aspirin, 300 mg of aspirin, or placebo.

Recruitment took place between 1979 and 1985, with the trial ending in 1986. The researchers performed a subgroup analysis of only those patients who took aspirin for at least 5 years.

The researchers reported that they identified trial participants who had developed cancer through cancer registries and death certificates.



The findings are not sufficient enough to warrant a recommendation.

Other events reported by 1% or more of patients with early Parkinson's disease and treated with Mirapex[®] (pramipexole dihydrochloride) tablets but reported equally or more frequently in the placebo group were infection, accidental injury, headache, pain, termor, back pain, spronce, postral hypotension, hypertonia, depression, abdomian pain, anviety, dyspepsia, flatulence, diarrhea, rash, ataxia, dv mouth, extrapyramidal syndrome, leg cramps, twitchling, nharyngitts, sinusits, sweating, rhinitis, urinary tract infection, associliation, flu syndrome, increased salva, tooth disease, dyspnea, increased creatine PK, nervousness, dream abnormalities, chest pain, neck pain, paresthesia, tachycardia, vertigo, voice alteration, conjunctivitis, parayisis, accommodation abnormalities, tinnits, diplopia, and taste pervensions. In a fibed-dose study in early Parkinson's disease, occurrence of the following events increased in frequency as the dose increased over the range from 1.5 mg/dst pt 6 mg/dsr. postral hypotension, placebo. Advanced Parkinson's disease: In the four double-blind, placebo-controlled trials of patients with advanced Parkinson's disease. In the four double-blind, placebo-controlled trials of patients with advanced Parkinson's disease, the most commonly observed adverse events (>55%) that were numerically more frequent in the group treated with MIRAPEX tablets and concomitant levodopa in double-blind, placebo-controlled trials of patients with advanced Parkinson's disease on the donormalities, confusion, asthenia, somnolence, dystoria, gait abnormalitie, bacebo and concombiled trials discontinued treatment were related to the nervous system (hallucinations, accidential livityr, dream abnormalities, confusion, constipation, asthenia, somnolence, dystoria, gait abnormalitie, sectora discobs and concomitant levodopa in the double-blind, placebo-controlled trials discontinued treatment were related to the nervous system (hallucinations [2.7% on MIRAPEX tablets vs 0.4% on placebo]; divinesia [1.2% on MIRAPEX

1.5% on placebo]: confusion [1.2% on MIRAPEX tablets vs 2.3% on placebo]: and cardiovascular system (postural (ortnostate) hypotension [2.3% on MIRAPEX tablets vs 1.4% on placebo]: Adverse-event Incidence in Controlled Clinical Studies in Advanced Parkinson's Disease: This section lists treatment-emergent adverse event lancidence in Controlled Clinical Studies in Advanced Parkinson's disease that were reported by 1% or more of patients treated with IMRAPEX tablets and were numerically more frequent than in the placebo group. In these studies, MIRAPEX tablets on placebo was administered to patients who were also receiving concomitant levodopa. Adverse events were usually mild or moderate in intensity. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be uced to provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the adverse-event incidence ret in the population studied. Treatment-emergent adverse events are listed by body system in order of decreasing incidence for MIRAPX tablets (N=260) vs placeto (N=264), respectively. Body as a whole caccidental injury (17% vs 15%), asthenia (10% vs 8%), general edem (4% vs 3%), chest pain (3% vs 2%), matabies (3% vs 2%), *Carclivascular system*: postnal hypotension (53% vs 44%), *Digestive system*: consultation (17% vs 4%), dw 5%), hypertonia (7% vs 6%), insomia (2% vs 2%), insomia (2% vs 2%

transient. Approximately 7% of 575 patients treated with MIRAPEX tablets during the double-blind periods of three placebo-controlled trials discontinued treatment due to adverse events compared to 5% of 223 patients who received placebo. The adverse event most commonly causing discontinuation of treatment was nausea (1%). This section lists treatment-emergent events that occurred in three double-blind, placebo-controlled studies in RLS patients that were reported by 2% or more of patients treated with MIRAPEX tablets and were numerically more frequent than in the placebo

escriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of u

The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. However, the cited figures do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the adverse-event incidence rate in the population studied. Treatment-frequent adverse-events are listed by body system in order of decreasing incidence for MIRAPEX tablets (N=575) vs placebo (N=223), respectively. *Gastrointestinal disorders*: nausea (16% vs 5%), constipation (4% vs 1%), diarrhea (3% vs 1%), dry mouth (3% vs 1%). *General disorders* and administration site conditions: tatigue (9% vs 7%). *Intections and infestations*: Influenza (3% vs 1%). *Networks system disorders*: headache (16% vs 15%), somolence (6% vs 5%). Platients may have reported multiple adverse experiences during the study or at discontinuation; thus, patients may be included in more than one category. This section summarizes data for adverse events that appeared to be dose related in the 12-week fixed dose study. Dese

than one category. This section summarizes data for adverse events that appeared to be dose related in the 12-week fixed dose study. Dose related adverse events in a 12-week (buble-blind, placebo-controlled, fixed dose study in Restless Legs Syndtrome (occurring in 5% or more of all platients in the treatment phase) are listed by body system in order of decreasing incidence for MIRAPEX (0.25 mg [N=88]; 0.5 mg [N=80]; 0.75 mg [N=90]) vs placebo (n=86), respectively. Gastrointestinal disorders: anasea (11%; 19%; 27% vs 5%), damhea (3%; 1%; 7% vs 0%), dyspepsia (3%; 1%; 4% vs 7%). Infections and infestations: influence 1%; 4%; 7% vs 1%). General disorders and administration site conditions: fatigue (3%; 5%; 7% vs 5%). Psychiatric disorders: insomnia (9%; 3%; 6% vs 1%). Musculoskeletal and connective tissue disorders: pain in extremity (3%; 3%; 7% vs 1%).

1%). Other events reported by 2% or more of RLS patients treated with Mirapex[®] (pramipexole dihydrochloride) tablets but equally or more frequently in the placebo group, were: vomiting, nasopharyngitis, back pain, pain in extremity, dizziness, and insomnia.

General Adverse Events; Relationship to Age, Gender, and Race: Among the treatment-emergent adverse events in patients treated with MRAPEX tablets, hallucination appeared to exhibit a positive relationship to age in patients with Parkinson's disease. Although no gender-related differences were observed in Parkinson's disease patients, nausea and fatigue, both generally transient, were more frequently reported by female than male RLS patients. Less than 4% of patients enrolled were non-Caucasian, therefore, an evaluation of adverse events related to arce is not cossible.

gender-related differences were observed in Parkinson's disease patients, nausea and tatigue, both generally transient, were inure frequently reported by female than male RLS patients. Less than 4% of patients enrolled were non-Caucasian, herefore, an evaluation of adverse events related to race is not possible. **Other Adverse Events Observed During Phase 2 and 3 Clinical Trials:** MIRAPEX tablets have been administered to 1620 Parkinson's disease patients and to 889 RLS patients in Phase 2 and 3 Clinical Trials: MIRAPEX tablets have been administered to 1620 Parkinson's disease patients and to 889 RLS patients in Phase 2 and 3 Clinical Trials. Unity these trials, all adverse events were recorded by the clinical investigators using terminology of their own choosing; similar types of events were grouped into a smaller number of standardized categories using MedDRA dictionary terminology. These categories are used in the listing below. Adverse events which are not listed above but occurred on at least two occasions (one occasion if the event was serious) in the 2509 individuals exposed to MIRAPEX tablets are listed below. The reported events below are included without regard to determination of a causal relationship to MIRAPEX tablets are listed below. The reported events below are included without regard to determination of a causal relationship to MIRAPEX tablets are listed below, and parket assister and and *ministered and hymptatic system disorders:* anenia, iron deficiency anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocytheemia, thrombocytheoralia. *Cardia Cionders:* angina pectoris, anrythmia supraventricular, tardia fibrilitation, rodal arritytimia, sinus arritytimia, sinus bradycardia, sinus tactivardia, supraventricular extrasystoles, supraventricular tachycardia, tachycardia, ventricular tablination, ventricular extrasystoles, eventricular relativas, exert and, nearing impaired hypoacusis, motion scioness, vestibula rataxia. *Endocrine disorders:* agointer disorders: arriad eq incontinence, gastric ulcer, gastric ulcer hemorrhage, gastritis, gastrointestinal hemorrhage, gastroesophageal reflux diseas gingivitis, haematemesis, haematochezia, hemorrhoids, hiatus hemia, hyperchlorhydria, ileus, inguinal hemia, intestinal obstructio

Initiaties. We want and a recommendation of the second second

Venin. Falling Asleep During Activities of Daily Living: Patients treated with Mirapex® (pramipexole dihydrochloride) tablets f reported falling asleep while engaged in activities of daily living, including operation of a motor vehicle which sometimes resu

Falling Asleep During Activities of Daily Living: Patients treated with Mirapex[®] (pramipexole dihydrochirde) tablets have reported falling asleep while engaged in activities of daily living, including operation of a motor vehicle which sometimes resulted in accidents (see boldet WARNING). Post-Marketing Experience: In addition to the adverse events reported during clinical trials, the following adverse reactions have been identified during post-approval use of MIRAPEX tablets, primarily in Parkinson's disease patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to pramipexole tablets. Similar types of events were grouped into a smaller number of standardized categories using the MedDRA dictionary: abnormal behavior, abnormal dreams, accidents (including failbu, blackouts, failque, hallucinations (all kinds), headache, hypotension (including postural hypotension), increased eating (including binge eating, compulsive eating, and hyperplagia), libido disorders (including increased and decreased libido, and hypersexuality), pathological gambling, syncope, and weight increase.

DRUG ABUSE AND DEPENDENCE

tance. Pramipexole has not been systematically studied in animals or humans for its potential endence. However, in a rat model on cocaine self-administration, pramipexole had little or no

OVERDOSAGE There is no clinical experience with massive overdosage. One patient, with a 10-year history of schizophrenia, took 11 mg/day of pramipexole for 2 days in a clinical trial to evaluate the effect of pramipexole in schizophreni patients. No adverse events were reported related to the increased dose. Blood pressure remained stable although pulse rate increased to between 100 and 120 beats/minute. The patient withdrew from the study at the end of week 2 due to lack of efficacy. There is no known antidote for overdosage of a dopamine agonist. If signs of central nervous system stimulation are present, a phenothizaine or other butyrophenone neuroleptic agent may be indicated; the efficacy of such drugs in reversing the effects of overdosage has not been assessed. Management of overdose may require general supportive measures along with gastric lavage, intravenous fluids, and electrocardiogram monitoring. **ANIMAL TOXICOLOGY Retinal Pathology in Albino Rats:** Pathologic changes (degeneration and loss of nhotorecenter celle) were choosed in the set

Intravenous fluids, and electrocardiogram monitoring. ANIMAL TOXICOLOGY Retinal Pathology in Abino Rats: Pathologic changes (degeneration and loss of photoreceptor cells) were observed in the retina of abino rats in the 2-year carcinogenicity study with pramipexole. These findings were first observed during week 76 and were dose dependent in animals receiving 2 or 8 mg/kg/day (plasma AUCs equal to 2.5 and 12.5 times the AUC in humans that received 1.5 mg TID). In a similar study of pigmented rats with 2 years' exposure to pramipexole at 2 or 8 mg/kg/day, retinal degeneration was not diagnosed. Animals given drug had thinning in the outer nuclear layer of the retina that was only slightly greater than that seen in control rats utilizing morphometry. Investigative studies demonstrated that pramipexole reduced the rate of disk shedding from the photoreceptor rod cells of the retina in albino rats, which was associated with enhanced sensitivity to the damaging effects of light. In a comparative study, degeneration and loss of photoreceptor cells occurred in albino rats after 13 weeks of treatment with 25 mg/kg/day of pramipexole (54 times the highest clinical dose on a mg/m² basis) and constant light (100 lux) but not in pigmented rats exposed to the same dose an higher light intensities (500 luw). Thus, the retina of albino rats is considered to be uniquely sensitive to the damaging effects of pramipexole and light. Similar changes in the retina did not occur in a 2-year carcinogenicity study in albino mice treated with 0.3, 2, or 10 mg/kg/day of pramipexole (0.4, 2.2, and 8.6 times the highest clinical dose on a mg/m² basis) for 12 months and minipigs given 0.3, 1, or 5 mg/kg/day of pramipexole (0.4, 2.2, and 1.6 times the highest clinical dose on a mg/m² basis). Lesions occurred in a line changes in the retine of albino cases albicked, but sets albited by tho changes. Fibro-osseous Proliferative Lesions in Mice: An increased indidence of fibro-osseous proliferative lesions occurred in the

Trademark under license from: Boehringer Ingelheim International GmbH U.S. Patent Nos. 4,886,812; 6,001,861; and 6,194,445.

© 2006, Boehringer Ingelheim International GmbH ALL RIGHTS RESERVED Revised November 7, 2006

Mirapex Boehringer Ingelheim

Rx only OT1317D MRLS-BS

Data Shed Light **On Incomplete** Colonoscopy

BY MARY ANN MOON Contributing Writer

erforming a colonoscopy in a private office or clinic rather than a hospital triples the likelihood that the procedure will be incomplete, reported Dr. Hemant A. Shah and associates in an article in the June issue of Gastroenterology.

The University of Toronto researchers conducted a population-based study to assess the effects of patient, endoscopist, and treatment-setting factors on the risk for incomplete colonoscopy. Their sample comprised more than 331,000 index colonoscopies, and more than 43,000 (13%) were incomplete.

Older patient age, female sex, and a history of abdominal or pelvic surgery were the main patient factors that raised the risk of incomplete colonoscopy. Regarding endoscopist factors, performing a low volume of the procedures and practicing general medicine rather than specializing in gastroenterology both increase the risk of incomplete colonoscopy, they reported.

The authors combined information from four Canadian databases to identify all residents of Ontario who underwent screening colonoscopy between 1999 and 2003 when they were aged 50-74 years. The mean patient age was 61 years, and 47% of the subjects were men. Procedures in which the colonoscope was inserted to the cecum or the terminal ileum were considered complete; procedures that fell short of those landmarks were considered incomplete.

In physician specialties, general surgeons performed the largest number of procedures (47%) and gastroenterologists performed the smallest (24%). The physician category combining internists, family physicians, and general practitioners accounted for the remaining 29% of colonoscopies. Community hospitals were the most common setting (72%). Another 15% of the procedures were performed in private offices, and 13% were done in academic hospitals.

The rates of incomplete colonoscopy were highest in the office setting (24.6%), compared with the community hospital (10.8%) and academic hospital (12.6%), regardless of patient or endoscopist characteristics. This high rate is of concern because of the rapid growth of office-based colonoscopy in many areas. That growth is fueled by limited access to endoscopy resources in many hospitals, particularly in academic medical centers, they added.

The researchers did not examine the reasons for incomplete colonoscopy but suggested that less or no sedation is used in offices, so more procedures are abandoned because of patient discomfort.

Endoscopists who performed a high volume of the procedures were the most likely to achieve complete colonoscopies. Among physicians with a low volume of these procedures, generalist physicians had an incomplete colonoscopy rate of nearly 30%, whereas general surgeons and gastroenterologists had incompletion rates of about 17% and 14%, respectively.